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Abstract Vascular endothelial growth factor (VEGF) is an
angiogenic stimulator which functions through two endothelial
specific tyrosine kinase receptors, Flt-1 and Flk-1. In this work,
we show that an 11-amino acid peptide derived from the second
immunoglobulin-like domain of Flt-1 functions as an angiogenic
inhibitor in chick chorioallantoic membrane and inhibited
VEGF-induced vascular permeability in Miles’ assay without
binding to VEGF directly. Circular dichroism and nuclear
magnetic resonance analyses indicate that this peptide forms a
stable extended structure in solution, presumably L-sheet
structure and is most likely existing as a dimer. Our results
suggest that this small peptide functions as an angiogenic
inhibitor by inhibiting VEGF function through a non-VEGF
binding mechanism. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Vascular endothelial growth factor (VEGF) (vascular per-
meability factor (VPF)) is a prime regulator of vasculogenesis,
angiogenesis and vascular permeability. It is a secreted growth
factor which functions as either paracrine or autocrine signals.
Native VEGF is a 40^45-kDa basic, heparin-binding, homo-
dimeric glycoprotein. Alternative splicing of the mRNA re-
sults in six isoforms of VEGF proteins in human [1,2].
Two high a⁄nity VEGF receptors have been identi¢ed:
VEGFR-1 (Flt-1, fms-like-tyrosine kinase) and VEGFR-2
(Flk-1/KDR, fetal liver kinase/kinase insert domain-contain-
ing receptor) [1,2]. The expression of these receptors is largely
limited to the surface of the blood vessel endothelial cells. in
vitro, both quiescent and proliferating endothelial cells have
been shown to display high a⁄nity binding for VEGF. The
expression of the VEGF receptors is no doubt one of the
earliest events in endothelial cell di¡erentiation [3,4]. Both
Flt-1 and Flk-1/KDR belong to the receptor tyrosine kinase
(RTK) superfamily and contain seven extracellular immuno-
globulin (Ig)-like domains, a single transmembrane region and
two cytoplasmic tyrosine kinase domains separated by a ki-
nase insert domain. VEGF e¡ects its bioactivity by inducing
receptor dimerization and tyrosine autophosphorylation of
the kinase domains. This in turn induces a cascade of signal
transductions that are not well understood.
Tumor growth and metastasis is angiogenesis dependent.
VEGF is up-regulated in many tumors and plays critical roles
in stimulating tumor angiogenesis [5]. In addition, its vascular
permeability e¡ect causes ‘leakiness’ in the incomplete base-
ment membrane of the newly formed tumor capillaries thus
facilitating metastasis [6]. Dominant-negative Flk-1 potently
inhibits tumor growth [7^9]. A small peptide derived from
the third Ig loop of Flk-1 inhibited VEGF165-stimulated signal
transduction and endothelial cell proliferation and migration
[10]. Similarly, soluble Flt-1 inhibits retinal neovascularization
and tumor angiogenesis [11,12]. Domain deletion studies of
Flt-1 have demonstrated that the ligand-binding function re-
sides in the ¢rst three Ig-like domains [1,13,14] and the 2nd
Ig-like domain (Flt-1D2) seems to play the most important
role amongst the three domains by determining the ligand
speci¢city of this receptor [15]. A complete and properly
folded recombinant Flt-1D2 is reported to be the minimum
domain required to bind VEGF and it binds VEGF at 60-
fold lower a⁄nity compared to wild-type receptor [16].
In this work, we show an 11-amino acid small peptide de-
rived from Flt-1D2 can function as an angiogenic inhibitor in
vivo. Interestingly, this peptide exhibits its e¡ects without
binding to VEGF or inhibiting VEGF’s binding to its recep-
tors.
2. Materials and methods
2.1. Peptide synthesis and puri¢cation
All the peptides were synthesized by a 433A peptide synthesizer
(Applied Biosystems Inc., USA). Database searches determined the
uniqueness of the peptides. The scrambled peptide is unique on its
own with no protein matches. The peptides were puri¢ed using high
pressure liquid chromatography (HPLC) on reversed-phase column
C18 using an acetonitrile gradient. The sequences of all peptides
were con¢rmed by their mass determined using electrospray mass
spectrometry.
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2.2. Chick chorioallantoic membrane (CAM) in vivo angiogenesis
assay
CAM assays were performed at both the 4th and 13th day of chick
embryo development. Peptides dissolved in sterile water were air-dried
onto sterile glass coverslides of approximately 1 mm2. The coverslides
were placed onto the well vascularized site of the CAM of the devel-
oping chick embryos. The possible anti-angiogenic response was eval-
uated 48 h later and recorded down with stereomicroscope photog-
raphy (Leica MZ12, Switzerland). The positive anti-angiogenic e¡ect
was scored when microvessels under the coverslides were obviously
reduced at 48 h after sample application on day 13 CAM or an
obvious blockage of CAM vessel development was observed on day
4 CAM.
2.3. Miles’ vascular permeability assay
Evans blue (0.5%) was injected intracardiacally into Hartley albino
guinea pigs of about 300^350 g. Test or control samples in water (100
Wl) were injected intradermally into shaved dorsal areas. 10 ng human
recombinant VEGF165 (hrVEGF165 ; Sigma, USA) consistently in-
duced intense vascular leakage within 5 min of application and was
used in all experiments. Various peptides at 100U, 1000U, 10 000U
or 100 000U molar excess was mixed with hrVEGF165 for testing. All
tests were done in duplicates in each experiment and repeated at least
three times.
2.4. Binding assays of VEGF and peptides
VEGF binding to human umbilical cord vascular endothelial cells
(HUVEC) was done essentially as previously described [17^20]. HU-
VECs (Clonetics, USA) were veri¢ed by their expression of endothe-
lial cell speci¢c markers such as von Willebrand factor (vWF) by
immunostaining and Flt-1 by RT-PCR before used in binding experi-
ments (data not shown). HUVECs (8U104) were seeded into 24-well
plates coated with gelatin. The cells were then incubated in the com-
plete culture medium (MCDB-131 plus 25 ng/ml aFGF, 50 Wg/ml
gentamicin, 17.6 U/ml heparin, 1% L-glutamine and 10% fetal bovine
serum) overnight. Cells were washed thoroughly with PBS and I125-
VEGF (80 WCi/Wg, NEN, USA) in 100 Wl of binding bu¡er (MCDB-
131+0.1% BSA) was added to the cells and incubated for 2 h at room
temperature. Test peptide was pre-mixed with I125-VEGF before add-
ing to HUVECs. An anti-human VEGF neutralizing monoclonal anti-
body (RpD Systems, USA) was used as a positive control for inhi-
bition. Following incubation, the cells were washed three times with
PBS and lysed in the lysis bu¡er (0.5% SDS). Cell-bound I125-VEGF
was measured using an automatic Q-counter. All tests were performed
in triplicates and repeated at least three times.
2.5. Structural analysis of the small peptides by circular dichroism
(CD) and nuclear magnetic resonance (NMR)
CD studies of the peptides were carried out on a JASCO J-720
spectropolarimeter. Peptides samples were prepared in phosphate
bu¡er at pH 7.0. Concentrations of the peptides were in the range
of 1^1.2 mg/ml. Path length of the cell was 1 mm. Spectra were
collected in the wavelength range of 200^280 nm. For dilution studies
of the peptides, samples were diluted to 1/5 of the original concen-
tration using phosphate bu¡er and spectra were recorded. Values of
ellipticity were expressed as molar ellipticity deg cm2/dmol. CD spec-
tra of the peptides were also recorded at pH 4.5 to compare with the
NMR results. Two-dimensional NMR spectra of the peptides were
recorded using a 500-MHz Bruker-Avance spectrometer. Concentra-
tions of the peptides were in the range of 1^1.4 mM. Peptides were
dissolved in 90% H2O/10% D2O and pH was adjusted to 4.5. Water
suppression was achieved by presaturation during relaxation delay.
Processing of the NMR spectra was carried out using xwin NMR
on silicon graphics computer.
3. Results
3.1. Small peptides derived from Flt-1D2 inhibited angiogenesis
in CAM
Peptides were designed based on (1) Flt-1 VEGF-binding
domain data by mutational analysis [15]; (2) the available
VEGF-Flt-1D2 protein crystal structure [16] (Fig. 1B); (3)
the ¢nding that proline residues are commonly found in the
£anking segments of protein^protein interaction sites [21]. Ac-
cording to the proline hypothesis and the amino acid sequence
of Flt-1D2, two sites were selected to be potential protein^
protein interaction sites. Both peptides, Flt1-12 (12 amino
acids) and Flt2-13 (13 amino acids), were synthesized and
found to be highly soluble in H2O (Fig. 1A). Database
searches indicated that these peptide sequences are unique
and found only in Flt-1D2. While Flt2-13 showed anti-angio-
genesis activity when tested on day 4 CAM, Flt1-12 is not
active (Fig. 2A and data not shown). When Flt2-13 was
then tested on day 13 CAM embryos, it resulted in angio-
genesis inhibition as well as vessel regression after 48 h (Fig.
2B). A randomly scrambled Flt2-13 peptide (sFlt2-13) com-
pletely lost this angiogenesis inhibition/vessel regression in-
duction activity (Figs. 1A and 2B). This indicated that the
anti-angiogenic/vessel regression activity of peptide Flt2-13 is
sequence dependent. Since proline brackets enhanced the po-
tency of short bioactive peptides, we replaced the N-terminal
proline into threonine [22]. As expected, peptide Flt2-13T had
a reduced activity in CAM (Figs. 1A and 2B).
To determine the smallest peptide which still retains the
angiogenesis inhibition/vessel regression activity, serial N-ter-
minal truncations of peptide Flt2-13 were made and tested on
day 13 CAM (Fig. 1A). Interestingly, peptide Flt2-11 showed
more potent activity than Flt2-13 while peptide Flt2-9 showed
comparable activity with Flt2-13 (Figs. 1A,B and 2B). Further
truncations of the peptide (Flt2-7 and Flt2-5) destroyed this
activity (data not shown). Application of the peptides some-
times caused non-speci¢c opaque core formation, in a dose-
dependent manner, which interfered in the data evaluation in
CAM. Therefore, only samples which did not cause opaque
core formation were recorded as having a positive vessel re-
Fig. 1. A: Amino acid sequences of peptides. B: Three-dimensional
structure of VEGF-Flt-1D2 complex. The original structure [16] is
modi¢ed to show the relevant parts of the complex only. The
VEGF molecule is in red and Flt-1D2 in blue. Peptide Flt2-11 is
shown as CPK; green shows the C-terminal amino acids of Flt2-11
which are in contact with VEGF; yellow shows the rest of the ami-
no acids in this peptide.
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Fig. 2. A: Peptide Flt2-11 inhibited CAM angiogenesis on day 4 and induced vessel regression on day 13. Arrows indicate the reduced micro-
vasculature 48 h after sample application to the CAM. B: Summary of the angiogenesis inhibition/vessel regression activity of various peptides
on day 13 CAM. The y-axis indicates the percentage of samples that showed vessel regression induction activity. Error bars are standard errors.
A minimum e¡ective sample number of 20 is tested for each peptide at each dose from repeated experiments.
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gression induction e¡ect. This resulted in a less number of
samples being counted in high peptide doses (25 and 50 Wg),
hence a lower percent of inhibition compared to 10 Wg peptide
(Fig. 2B and data not shown). However, the relative activities
of the various peptides are generally consistent in the various
doses tested. Thus three peptides derived from the same re-
gion of Flt-1D2, at 13, 11 and 9 amino acids in length respec-
tively, function as angiogenic inhibitors/vessel regression in-
ducers in CAM. Amongst them, peptide Flt2-11 has the
highest activity.
3.2. Peptide Flt2-11 inhibits vascular permeability induced by
VEGF
The active anti-angiogenic peptides selected above were
then tested on their ability to inhibit hrVEGF165-induced vas-
cular permeability using the Miles’ vascular permeability as-
say [23,24]. 10 ng of hrVEGF165 was injected intradermally
into the dorsal or £anking skin of guinea pigs to induce a
signi¢cant and consistent leakage of pre-injected Evan’s blue
dye within 5 min. The three peptides showed no induction of
vascular leakage by themselves (data not shown).
Various doses of peptides were pre-mixed with hrVEGF165
before injecting intradermally into guinea pigs. Only peptide
Flt2-11 showed complete inhibition of hrVEGF165-induced
vascular hyperpermeability at 100 000-fold molar excess of
VEGF. At this dose, no vascular leakage was observed even
after 2 h of injection of hrVEGF (Fig. 3). Similar doses of
four other peptides tested including Flt2-13, Flt2-9, Flt2-13T,
Flt1-12 all failed to show any inhibitory e¡ect under the same
testing conditions (Fig. 3 and data not shown).
Fig. 2 (continued).
Fig. 3. Peptide Flt2-11 inhibited VEGF165-induced vascular permeability in Miles’ assay. Actual photos of the experiments are shown on the
left and the schematic representations are shown on the right. Arrows indicate the positions in which injection of the samples produced no vas-
cular leakage of the guinea pig skin. The fold numbers indicate the molar excess of peptide over recombinant human VEGF165 in the samples.
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These results indicate that peptide Flt2-11 was able to in-
hibit VEGF-induced vascular permeability in vivo. This is
consistent with previous CAM assays, which showed that
amongst all the peptides tested, Flt2-11 has the highest angio-
genesis inhibitory activity.
3.3. Peptide Flt2-11 does not bind to VEGF nor does it inhibit
VEGF’s binding to its receptors on HUVEC cells
To test whether Flt2-11 inhibits VEGF function by inter-
fering with VEGF binding to its receptors, we examined I125-
VEGF binding to HUVEC cells in the presence or absence of
the peptides using identical experimental binding conditions
used earlier where truncated Flt-1 (sFlt-1) has been shown to
inhibit I125-VEGF’s binding to these cells [17^20]. The cells
used were pre-tested for endothelial cell speci¢c markers and
expression of Flt-1 mRNA (data not shown). No peptides
(including Flt2-11) showed signi¢cant inhibition of I125-
VEGF binding to HUVEC cells even at 100 000-fold molar
excess (Fig. 4). In contrast, an anti-VEGF monoclonal anti-
body e¡ectively inhibited I125-VEGF binding under the same
binding conditions.
The ability of the peptides to bind I125-VEGF was also
analyzed. Peptides were blotted onto a nitrocellulose mem-
brane or coated onto the surface of a 96-well plate and then
incubated with I125-VEGF in binding bu¡ers. No signi¢cant
retention of I125-VEGF was detected in either binding assays
compared to BSA control even with very high amounts of
peptides (data not shown). These results indicate that peptide
Flt2-11 most likely neither binds to VEGF and nor does it
interfere with VEGF’s binding to its receptors on HUVEC
cells.
3.4. Peptide Flt2-11 forms extended or L-sheet structure in
solution
The three-dimensional structure shows that parts of peptide
Flt2-11 reside at the third L-sheet in Flt-1D2 [16]. The VEGF
interaction site (residues 171^173) of Flt-1D2 is localized at the
C-terminal end of this peptide (Fig. 1B). To determine
whether structural di¡erences between the peptides could con-
tribute to their anti-angiogenic activity, we examined their
structures by CD and two-dimensional NMR. At 1.2 mg/ml,
peptide Flt2-13 showed a negative band around 225^230 nm
while peptides Flt2-11 and Flt2-9 showed two negative bands,
one around 225^230 nm and the second band around 215^217
nm (Fig. 5A). Peptide Flt2-7 showed a small negative band
around 230 nm and a large negative band around 210 nm. In
the case of peptide Flt2-13, the negative band around 225 nm
had an especially large intensity. The negative band around
225^230 nm usually indicates the possibility of peptide acquir-
ing a L-turn structure [25]. As the peptide was truncated from
the N-terminal end, the intensity of the 225-nm negative band
decreased (Fig. 5A). In Flt2-11, in addition to the negative
CD band at 228 nm, a new band at 217 nm appeared suggest-
ing a L-sheet in addition to the L-turn structure. Peptide Flt2-
9 showed similar spectrum to that of Flt2-11 with two neg-
ative bands, one around 228 nm and the other around 215
nm. In peptide Flt2-7, the negative band around 230 nm be-
came very small in intensity and the intensity around the 210-
nm band increased (Fig. 5A) indicating a more £exible/unor-
dered structure. Upon dilution, the CD spectra of peptide
Flt2-11 showed drastic changes in the intensity of the 225-
nm negative band indicating loss of L-sheet conformation
(Fig. 5B). The band around 205 nm suggested that upon di-
lution the peptide acquires a more £exible/unordered struc-
ture.
Fig. 4. VEGF165 binding to HUVEC cells is not inhibited with ex-
cess peptides. VEGF165 binding to HUVEC in the presence of BSA
is taking as 100% binding. The bindings of VEGF165 in the presence
of 100 000-fold molar excess of various peptides as well as anti-
VEGF antibody at 80 ng/ml were shown as percentage of the con-
trol binding. Error bars are standard errors.
Fig. 5. CD spectra of the peptides in solution. A: CD spectra of
various peptides at 1 mg/ml. Flt2-13 (8) ; Flt2-11 (- - - - -) ; Flt2-9
(......) ; Flt2-7 (8W). B: CD spectra of peptide Flt2-11 upon dilution
of the peptide to 0.2 mg/ml indicating change in structure upon di-
lution. (- - - - -) Peptide at 1 mg/ml; (8W) peptide at 0.2 mg/ml.
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To further understand the secondary structure of the pep-
tides, two-dimensional NMR studies were carried out. RO-
ESY spectra of the peptides showed sequential connectivities
indicating extended structure in the peptides. Peptide Flt2-13
showed NH^NH connectivities in the ROESY spectrum indi-
cating the presence of L-turn in the peptide structure (data not
shown). All the other three peptides (Flt2-11, Flt2-9 and Flt2-
7) did not show any NH^NH connectivity suggesting that
these peptides acquire an extended structure [26]. Combining
the CD and NMR results, peptides Flt2-11, Flt2-9 and Flt2-7
most likely acquire extended (L-sheet) structure in solution at
the higher concentration while peptide Flt2-13 may have a L-
turn structure. It is interesting to note that it is unusual to
observe such stable L-sheet structure of small peptides in so-
lution. The detailed NMR analysis will be presented else-
where.
4. Discussion
There have been reports of small peptides derived from
large proteins which can function as inhibitors of the large
proteins. For example, a 17-residue peptide derived from the
third Ig-like domain of Flk-1 inhibited VEGF-stimulated au-
tophosphorylation of Flk-1 (VEGFR-2) as well as prolifera-
tion and migration of cultured microvascular endothelial cells
[10]. This Flk-1 peptide binds to VEGF and the covalently
dimerized form of this peptide inhibited 125I-VEGF binding to
HUVEC cells. So this peptide functions as VEGF inhibitor by
competitively binding to VEGF receptors on endothelial cells
[10]. In another example, a peptide corresponding to VEGF165
exon-7 inhibited VEGF function by inhibiting VEGF’s bind-
ing to HUVEC cells [27].
In this work, we have identi¢ed an 11-amino acid peptide,
Flt2-11, derived from the second Ig-like domain of human
Flt-1 which can inhibit CAM angiogenesis as well as
VEGF-induced vascular permeability. Although initial CAM
angiogenesis assays showed that peptides Flt2-13, Flt2-11 and
Flt2-9 all have angiogenesis inhibition/vessel regression activ-
ities, only Flt2-11 was able to inhibit VEGF-induced vascular
permeability in Miles’ assay. Incidentally, Flt2-11 also has the
highest angiogenesis inhibition/vessel regression activity in
CAM. The extreme high sensitivity and potency of VEGF
induced vascular permeability in Miles’ assay is probably
the reason why high amounts of Flt2-11 peptide are needed
to completely inhibit the dye leakage. Since this segment of
Flt-1 was involved in the complex formation with VEGF [16],
we expected the peptide to bind to VEGF and interfere with
its interaction with Flt-1. Surprisingly, Flt-11 peptide does not
bind to VEGF nor does it inhibit I125-VEGF binding to HU-
VEC cells in our tested conditions. As peptide Flt2-11 con-
tains no cysteine residues and therefore is not able to form
any disul¢de bond, our result is consistent with previous re-
ports that a complete Flt-1D2 is the minimum domain re-
quired to bind VEGF [13,14,16]. Therefore, peptide Flt2-11
possibly interferes with VEGF-stimulated angiogenesis and
vascular permeability through a non-VEGF binding mecha-
nism.
The molecular mechanisms of VEGF-induced vascular per-
meability are not well understood. Particularly, the receptors
involved in this VEGF signaling are essentially unknown. Re-
cently, a VEGF mutant which lacks Flk-1 activation was
shown to retain the ability to induce vascular permeability
[28]. This ¢nding uncouples VEGF-induced vascular leakage
to mitogenesis. It seems possible then that VEGF induces
vascular leakage through receptors other than Flk-1 on the
endothelial cell surface such as Flt-1. However, as both pla-
cental growth factor (PlGF) and VEGF-B, members of the
VEGF family which only bind Flt-1, lack any signi¢cant per-
meability inducing activity, whether Flt-1 is involved in
VEGF-induced vascular leakage needs further investigation.
In this regard, peptide Flt2-11 may be a useful tool to study
the molecular mechanism of VEGF-induced vascular perme-
ability.
CD and NMR analyses of the peptides indicate that Flt2-13
shows signi¢cant L-turn in its structure, whereas Flt2-11 and
Flt2-9 form L-sheets in solution (Fig. 5). Further, peptide
Flt2-11 most likely exists as a stable dimer in solution as
shown by dilution experiments (Fig. 5B) and ROESY data
(not shown). Interestingly, this increase in the extended L-
sheet conformation in Flt2-11 showed concurrent increase in
the anti-angiogenic e¡ects. Further truncations of the peptides
resulted in lower L-sheet content as well as decrease in activ-
ity. The decrease in L-sheet content can be explained by the
decrease in the number of hydrogen bond interactions. Loss
of critical amino acid or L-sheet structure during further trun-
cation might explain the decrease or loss of anti-angiogenic
activity in Flt2-9 and Flt2-7. It is important to note that these
peptides still have the residues that are involved in ‘actual’
contact between VEGF and Flt-1D2 [16]. Our results indicate
the extended structure in this segment somehow contributes to
the inhibition of VEGF activity. On the other hand, Flt2-11
acts by a distinctly di¡erent mechanism other than one ex-
pected based on direct interaction, since it did not inhibit
VEGF’s binding to its receptors on HUVEC cells nor did it
bind to VEGF itself. The contribution of the unusual, but
stable L-sheets formed by dimeric interactions in solution is
also not clear. The possibility that peptide Flt2-11 can inter-
fere with VEGF receptor dimerization cannot be excluded.
Our experiments also do not address the possible internaliza-
tion and interference of intracellular signaling by this peptide.
Further studies are needed to clarify these in order to under-
stand the mechanism of this peptide inhibition of VEGF func-
tion. Irrespective, derivatives or mimics of this peptide with
improved anti-angiogenic potency may help us to develop
prototypes of anti-angiogenic drugs.
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